TIAA CREF Investment Management LLC Acquires 105,895 Shares of Endologix, Inc. (ELGX)

TIAA CREF Investment Management LLC lifted its holdings in Endologix, Inc. (NASDAQ:ELGX) by 48.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 324,193 shares of the medical instruments supplier’s stock after buying an additional 105,895 shares during the quarter. TIAA CREF Investment Management LLC owned approximately 0.39% of Endologix worth $1,576,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Swiss National Bank grew its position in shares of Endologix by 14.3% in the 2nd quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock worth $670,000 after buying an additional 17,300 shares during the period. American International Group Inc. grew its position in shares of Endologix by 7.1% in the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 3,290 shares during the period. Stephens Inc. AR grew its position in shares of Endologix by 10.5% in the 2nd quarter. Stephens Inc. AR now owns 845,016 shares of the medical instruments supplier’s stock worth $4,107,000 after buying an additional 80,328 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Endologix by 10.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock worth $1,562,000 after buying an additional 30,429 shares during the period. Finally, Teachers Advisors LLC grew its position in shares of Endologix by 40.8% in the 2nd quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock worth $967,000 after buying an additional 57,675 shares during the period.

Endologix, Inc. (NASDAQ:ELGX) opened at $5.92 on Friday. Endologix, Inc. has a one year low of $4.08 and a one year high of $10.36. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 2.28.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The firm had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $47.58 million. During the same quarter in the prior year, the business earned ($0.20) EPS. The business’s quarterly revenue was down 4.6% on a year-over-year basis. equities analysts forecast that Endologix, Inc. will post -0.71 EPS for the current year.

A number of analysts have recently weighed in on ELGX shares. Zacks Investment Research raised shares of Endologix from a “hold” rating to a “strong-buy” rating and set a $5.75 target price on the stock in a research report on Monday, July 24th. Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 price target on shares of Endologix in a research note on Monday, July 31st. Stifel Nicolaus set a $6.00 price target on shares of Endologix and gave the stock a “hold” rating in a research note on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $5.00 price target on shares of Endologix and gave the stock a “hold” rating in a research note on Thursday, August 3rd. Finally, Canaccord Genuity reiterated a “hold” rating on shares of Endologix in a research note on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating and eleven have given a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $6.28.

ILLEGAL ACTIVITY NOTICE: “TIAA CREF Investment Management LLC Acquires 105,895 Shares of Endologix, Inc. (ELGX)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/11/05/tiaa-cref-investment-management-llc-acquires-105895-shares-of-endologix-inc-elgx.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix, Inc. (NASDAQ:ELGX).

Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

What are top analysts saying about Endologix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endologix Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit